Identification and characterisation of transient receptor potential melastatin 2 and CD38 channels on natural killer cells using the novel application of flow cytometry

被引:1
|
作者
Balinas, Cassandra [1 ,2 ]
Cabanas, Helene [1 ,2 ]
Staines, Donald [1 ,2 ]
Marshall-Gradisnik, Sonya [1 ,2 ]
机构
[1] Griffith Univ, Sch Med Sci, Gold Coast, Qld, Australia
[2] Griffith Univ, Menzies Hlth Inst Queensland, Natl Ctr Neuroimmunol & Emerging Dis, Southport, Qld 4222, Australia
关键词
Antibody; Flow cytometry; Natural killer cells; Transient receptor potential Melastatin 2; CA2+ INFLUX; TRPM2; CONTRIBUTES; CANCER-CELLS; ADP-RIBOSE; CALCIUM;
D O I
10.1186/s12865-019-0293-0
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
BackgroundNatural Killer (NK) cells are effector lymphocytes of the innate immune system and are subclassed into CD56(Bright)CD16(Dim/-) and CD56(Dim)CD16(+) NK cells. Intracellular calcium (Ca2+) is fundamental to regulate a number of intracellular signalling pathways and functions in NK cells, which are essential in mediating their natural cytotoxic function. Transient receptor potential melastatin 2 (TRPM2) is a Ca2+-permeable non-selective cation channel that possesses a critical role in calcium-dependent cell signalling to maintain cellular homeostasis. TRPM2 and CD38 protein surface expression has yet to be determined on NK cells using flow cytometry. Characterisation of TRPM2 has been previously identified by in vivo models, primarily using methods such as genetic remodification, immunohistochemistry and whole cell electrophysiology. The aim of this study was to develop an in vitro methodology to characterise TRPM2 and CD38 surface expression on NK cell subsets using an antibody that has not been previously applied using flow cytometry.ResultsAt 2h/1h, TRPM2 (Fig. 2 A, B, p <0.05) and TRPM2/CD38 (Fig.3A, B, p <0.05) surface expression significantly increased between 1:300 and 1:50 at 2h/1h. TRPM2/CD38 surface expression furthermore increased between 1:100 and 1:50 at 2h/1h (Fig.3A, p <0.05). Interestingly, TRPM2/CD38 surface expression significantly decreased from 1:50 to 1:5 on CD56(Bright)CD16(Dim/-) NK cells. These consistent findings highlight that 1:50 is the optimal antibody dilution and threshold to measure TRPM2 and TRPM2/CD38 surface expression on NK subsets. 2h/1h was determined as the optimal incubation period to ensure a sufficient timeframe for maximal antibody binding and surface expression.ConclusionFor the first time, we describe an in vitro methodology to characterise TRPM2 and CD38 surface expression on NK cells in healthy participants. Finally, using an antibody that has not been previously applied in flow cytometry, we determined an antibody concentration and incubation time that is robust, rapid and sensitive for the application of flow cytometry.
引用
收藏
页数:10
相关论文
共 34 条
  • [31] A novel human CD34(+) subset that constitutively expresses the high affinity interleukin-2 receptor traffics to lymph nodes and differentiates into CD56Bright natural killer cells.
    Freud, AG
    Becknell, B
    Roychowdhury, S
    Mao, HC
    Ferketich, AK
    Nuovo, GJ
    Hughes, TL
    Marburger, TB
    Sung, J
    Baiocchi, RA
    Guimond, M
    Caliguri, MA
    BLOOD, 2004, 104 (11) : 93A - 93A
  • [32] PHASE 2 STUDY OF SL-701, A NOVEL IMMUNOTHERAPY, IN ADULTS WITH RECURRENT GBM: A HIGH PARAMETER FLOW CYTOMETRY ANALYSIS OF CD8+T CELLS AND POTENTIAL IMPLICATIONS FOR PATIENT ENRICHMENT STRATEGIES
    Peereboom, David
    Lindsay, Ross
    Badruddoja, Michael
    Nabors, L. Burt
    Kumthekar, Priya
    Lieberman, Frank
    Tran, David
    Phuphanich, Surasak
    Schiff, David
    Sherman, Jonathan
    Butowski, Nicholas
    Dunbar, Erin
    Fink, Karen
    Iwamoto, Fabio
    Moertel, Christopher
    Schulder, Michael
    Walbert, Tobias
    Habboubi, Nassir
    Grzegorzewski, Krzysztof
    Brooks, Christopher
    Reardon, David
    NEURO-ONCOLOGY, 2021, 23 : 51 - 51
  • [33] A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo
    von Strandmann, EP
    Hansen, HP
    Reiners, KS
    Schnell, R
    Borchmann, P
    Merkert, S
    Simhadri, VR
    Draube, A
    Reiser, M
    Purr, I
    Hallek, M
    Engert, A
    BLOOD, 2006, 107 (05) : 1955 - 1962
  • [34] Off-the-Shelf Natural Killer Cells with Multi-Functional Engineering Using a Novel Anti-CD19 Chimeric Antigen Receptor Combined with Stabilized CD16 and IL15 Expression to Enhance Directed Anti-Tumor Activity
    Kaufman, Dan S.
    Bjordahl, Ryan
    Zhu, Huang
    Blum, Robert
    Bahena, Andres
    Mahmood, Sajid
    Bonello, Greg
    Lee, Tom
    Walcheck, Bruce
    Cichocki, Frank
    Miller, Jeffrey S.
    Valamehr, Bahram
    BLOOD, 2018, 132